Evidence Hub

Analysis of Patient Education Guides Generated by ChatGPT and Gemini on Common Anti-diabetic Drugs: A Cross-Sectional Study

Jyothis G. Saji, Aswini Balagangatharan, S. Bajaj, Vibha Swarnkar, Devika A S Unni, Aswathy Dileep

Cureus, 2025

8 citations

Abstract

Introduction Patient information guides are required, as they help to identify early diseases and complications and to prevent them. Artificial intelligence (AI) tools are being used to create patient education guides for easy accessibility to people. Methodology This was a cross-sectional study analyzing patient information guides regarding six anti-diabetic drugs created using ChatGPT (OpenAI, Inc., San Francisco, California, United States) and Gemini (Google LLC, Mountain View, California, United States), respectively. The patient information guides were on anti-diabetic drugs, including metformin, empagliflozin, liraglutide, glipizide, sitagliptin, and insulin glargine, and were created with the help of various prompts. Results There was no statistically significant difference found between any of the characteristics of the responses generated by the two AI tools, according to the P values obtained. Conclusion On comparing the two AI tools, there was not much difference noted in readability, reliability, and similarity.

How strong is the evidence?

Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free